Northview LifeSciences

No. The firm describes itself as a strategic investment and consulting platform, not a closed-end fund. Its model combines direct investment with commercial-strategy advisory services, and it does not publicly disclose a committed capital pool, fund structure, or limited-partner base.

Northview's disclosed portfolio ranges from monoclonal antibody platforms, targeted alpha radiation oncology therapies, and ophthalmic specialty drugs to cardiovascular and neurosurgical devices. It also backs digital-health tools, surgical imaging, human-performance supplements, urban agriculture technology, and healthcare staffing — a wider aperture than most dedicated life-science funds.

Northview has not publicly named its principals, investment committee, or deal-team leads. Its materials cite former investment bankers and biotech executives as the core of the group, but no individual biographies or titles are listed on its website as of this profile's publication.